Establishing a Role for Radical Prostatectomy in Low-volume Metastatic Disease: From Premise to Proof?
-
Published:2024-01
Issue:
Volume:59
Page:5-6
-
ISSN:2666-1683
-
Container-title:European Urology Open Science
-
language:en
-
Short-container-title:European Urology Open Science
Author:
Kesch ClaudiaORCID,
Calleris Giorgio,
Pradere Benjamin,
Ploussard Guillaume
Reference8 articles.
1. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial;Parker;Lancet,2018
2. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial
3. Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): results of PEACE-1, a phase 3 randomized trial with a 2x2 design;Bossi;J Clin Oncol,2023
4. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design;Fizazi;Lancet,2022
5. Combination of androgen deprivation therapy with radical local therapy versus androgen deprivation therapy alone for newly diagnosed oligometastatic prostate cancer: a phase II randomized controlled trial;Dai;Eur Urol Oncol,2022